SAS

2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID

Find entries where: SAS

is present as a standalone ligand in 6 entries

Find related ligands:

Chemical Component Summary
Name	2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID
Synonyms	SULFASALAZINE
Identifiers	2-hydroxy-5-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl-benzoic acid
Formula	C₁₈ H₁₄ N₄ O₅ S
Molecular Weight	398.393
Type	NON-POLYMER
Isomeric SMILES	c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)/N=N/c3ccc(c(c3)C(=O)O)O
InChI	InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChIKey	NCEXYHBECQHGNR-QZQOTICOSA-N

Chemical Details
Formal Charge	0
Atom Count	42
Chiral Atom Count	0
Bond Count	44
Aromatic Bond Count	18

Drug Info: DrugBank

DrugBank ID	DB00795
Name	Sulfasalazine
Groups	approved
Description	Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine.[A255582] Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD).[A255582] Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD.[A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970.[A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease.[A255592] Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
Synonyms	Salicylazosulfapyridine 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid Sulfasalazine Sulfasalazina 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid Salazosulfapyridine Sulfasalazinum Salazosulfapyridinum Sulfasalazin Salazosulfapiridina 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid Azopyrin 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
Brand Names	PMS-sulfasalazine 500mg/tab USP Sas Tab 500mg Salazopyrin Enema 3gm/100ml Apo Sulfasalazine Tab 500mg Sulfasalazine Delayed-Release Sulfasalazine EC Salazopyrin En-tabs 500 mg S.A.S. Enteric 500mg Ratio-sulfasalazine Tab 500mg Azulfidine Sulfasalazine Orb-sulfasalazine EC PMS-sulfasalazine-E.C. Tab 500mg Ratio-sulfasalazine En Salazopyrin Tab 500mg Azulfidine EN-tabs Sas Enema 3gm/100ml Salazopyrin Enema 3.0gm/100ml
Indication	In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis.[L39065] Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.[L39065]For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pediatric patients who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs or polyarticular-course juvenile rheumatoid arthritis with the same patients' characteristics.[L39065]
Categories	Agents causing hyperkalemia Agents that produce hypertension Alimentary Tract and Metabolism Amides Aminosalicylate Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal (Non-Selective) Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents Antirheumatic Agents BCRP/ABCG2 Inhibitors BCRP/ABCG2 Substrates Gastrointestinal Agents Immunosuppressive Agents Intestinal Antiinflammatory Agents Methemoglobinemia Associated Agents Nephrotoxic agents Non COX-2 selective NSAIDS NTCP Inhibitors OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors Salicylates Sulfonamides Sulfones Sulfur Compounds
ATC-Code	G01AE10 A07EC01
CAS number	599-79-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Arachidonate 5-lipoxygenase	MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGA...	unknown	inhibitor
Prostaglandin G/H synthase 2	MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFY...	unknown	inhibitor
Prostaglandin G/H synthase 1	MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFG...	unknown	inhibitor
Acetyl-CoA acetyltransferase, mitochondrial	MAVLAALLRSGARSRSPLLRRLVQEIRYVERSYVSKPTLKEVVIVSATRT...	unknown	inhibitor
Phospholipase A2	MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCY...	unknown	antagonist
Cystine/glutamate transporter	MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGV...	unknown	inhibitor
Nuclear factor NF-kappa-B p105 subunit	MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQP...	unknown	inhibitor
Nuclear factor NF-kappa-B p100 subunit	MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRG...	unknown	inhibitor
Inhibitor of nuclear factor kappa-B kinase subunit beta	MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQEL...	unknown	inhibitor
Inhibitor of nuclear factor kappa-B kinase subunit alpha	MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLEL...	unknown
Peroxisome proliferator-activated receptor gamma	MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDL...	unknown	agonist
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate,inhibitor
Canalicular multispecific organic anion transporter 1	MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLH...	unknown	substrate
Proton-coupled folate transporter	MEGSASPPEKPRARPAAAVLCRGPVEPLVFLANFALVLQGPLTTQYLWHR...	unknown	inhibitor
Solute carrier organic anion transporter family member 1B1	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...	unknown	inhibitor
Solute carrier organic anion transporter family member 1B3	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKI...	unknown	inhibitor
Solute carrier organic anion transporter family member 2B1	MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKL...	unknown	inhibitor
Sodium/bile acid cotransporter	MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSK...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682